For instance, certain mutations in ErbB1 (EGFR) and the amplification/overexpression of ErbB2 provide important targets for interrogation in non-small cell lung cancer (NSCLC) and breast cancer, respectively [20,21,22]. Here, ERBB2 is linked to non-small cell lung carcinoma.